The Future of the Quinolones Vincent T. Andriole State-of-The-Art Presentations 18 November 2012 Pages: 1 - 7
Quinolone Mode of Action — New Aspects David C. Hooper State-of-The-Art Presentations 18 November 2012 Pages: 8 - 14
Mechanisms of Resistance to Quinolones E. CambauL. Gutmann State-of-The-Art Presentations 18 November 2012 Pages: 15 - 23
The Epidemiology of Bacterial Resistance to Quinolones J. F. AcarT. F. O’BrienR. N. Jones State-of-The-Art Presentations 18 November 2012 Pages: 24 - 28
Quinolones in Intracellular Infections Jean-Claude Pechère State-of-The-Art Presentations 18 November 2012 Pages: 29 - 36
Use of the Quinolones in Paediatrics Urs B. Schaad State-of-The-Art Presentations 18 November 2012 Pages: 37 - 41
The Use of Quinolones in Developing Countries E. Rodríguez-NoriegaR. Morfín-OteroS. Esparza-Ahumada State-of-The-Art Presentations 18 November 2012 Pages: 42 - 45
Postmarketing Surveillance of Quinolones, 1990 to 1992 Peter DaveyTom McDonald State-of-The-Art Presentations 18 November 2012 Pages: 46 - 53
Synergy and Antagonism of Fluoroquinolones with Other Classes of Antimicrobial Agents Harold C. Neu State-of-The-Art Presentations 18 November 2012 Pages: 54 - 58
Safety and Tolerability of Fluoroquinolones S. Ragnar NorrbyPaul S. Lietman State-of-The-Art Presentations 18 November 2012 Pages: 59 - 64
Fluoroquinolones: Interaction Profile during Enteral Absorption Karl-Matthias DeppermannHartmut Lode State-of-The-Art Presentations 18 November 2012 Pages: 65 - 72
Use of the Quinolones for the Prophylaxis and Therapy of Infections in Immunocompromised Hosts Georg Maschmeyer State-of-The-Art Presentations 18 November 2012 Pages: 73 - 80
Use of the Quinolones in the Prophylaxis and Treatment of Granulocytopenic Immunocompromised Cancer Patients P. Van der AuweraJ. Gérain State-of-The-Art Presentations 18 November 2012 Pages: 81 - 90
Quinolones in the Treatment of Lower Respiratory Tract Infections in Adult Patients Claude Carbon State-of-The-Art Presentations 18 November 2012 Pages: 91 - 97
Fluoroquinolones in the Treatment of Cystic Fibrosis N. HøibyS. S. PedersenC. Koch State-of-The-Art Presentations 18 November 2012 Pages: 98 - 101
Fluoroquinolones and Surgical Prophylaxis P. DellamonicaE. Bernard State-of-The-Art Presentations 18 November 2012 Pages: 102 - 113
Quinolones in the Treatment of Acute Bacterial Diarrhoeal Diseases H. Erdal Akalin State-of-The-Art Presentations 18 November 2012 Pages: 114 - 118
Quinolones in Salmonella typhi Infection Herbert L. DuPont State-of-The-Art Presentations 18 November 2012 Pages: 119 - 124
Impact of the Fluoroquinolones on Gastrointestinal Flora Volkan KortenBarbara E. Murray State-of-The-Art Presentations 18 November 2012 Pages: 125 - 133
Quinolones in Sexually Transmitted Diseases Geoffrey L. Ridgway State-of-The-Art Presentations 18 November 2012 Pages: 134 - 138
Management of Lower Urinary Tract Infections Ross R. Bailey State-of-The-Art Presentations 18 November 2012 Pages: 139 - 144
Hydrophobicity of 11 Fluoroquinolones and Antibacterial Activity, Activity against DNA Gyrase and Uptake S. BazileN. J. MoreauM. Essiz Poster Presentations 18 November 2012 Pages: 145 - 147
Affinity of Sparfloxacin and 4 Other Fluoroquinolones for Magnesium and Effect on Antibacterial Activity S. LecomteC. CoupryN. J. Moreau Poster Presentations 18 November 2012 Pages: 148 - 149
Effect of Cations and EDTA upon the Activity of 18 Quinolones, Gentamicin, Ceftazidime and Polymixin against Gram-Negative and Gram-Positive Bacteria A. J. H. MarshallL. J. V. Piddock Poster Presentations 18 November 2012 Pages: 150 - 151
Sensitivity of Community- and Hospital-Acquired Bacterial Isolates to Sparfloxacin in Comparison with Other Antibiotics Josef FochtKristof NösnerMichael Kresken Poster Presentations 18 November 2012 Pages: 152 - 156
Antimicrobial Activities of Ciprofloxacin and 6 Other New Quinolones In Vitro against Recent Clinical Pathogens Satoshi NakashioSeiji HoriJingoro Shimada Poster Presentations 18 November 2012 Pages: 157 - 158
Comparative In Vitro Activity of Ofloxacin and Other Antimicrobial Agents Used in Oral Therapy in General Practice J. FochtH. KrausK. Nösner Poster Presentations 18 November 2012 Pages: 159 - 160
6 Years of Experience with Sensitivity Testing of Various Gram-Negative and Gram-Positive Clinical Strains to Ofloxacin M. L. ZarembaM. RozkiewiczJ. Borowski Poster Presentations 18 November 2012 Pages: 161 - 162
MIC Audit of Routine Ciprofloxacin Sensitivity Testing A. KingI. PhillipsG. Tillotson Poster Presentations 18 November 2012 Pages: 163 - 164
Annual Changes in the Susceptibility of Clinical Isolates to Ofloxacin Takayuki Takubo Poster Presentations 18 November 2012 Pages: 165 - 166
The North American Component (USA, Canada) of an International Comparative MIC Trial Monitoring Ofloxacin Resistance Daryl HobanRonald N. Jones Poster Presentations 18 November 2012 Pages: 167 - 169
Surveillance of Bacterial Resistance to Quinolones Fu WangDe-Mei ZhuYu-qing Wang Poster Presentations 18 November 2012 Pages: 170 - 171
Clinical and Experimental Study of the Appearance of Norfloxacin-Resistant P. aeruginosa in UTI S. OnoderaH. KiyotaS. Iyobe Poster Presentations 18 November 2012 Pages: 172 - 173
Prevalence of Ciprofloxacin Resistance in Multiresistant Gram-Negative Intensive Care Unit Isolates C. M. KhuranaB. R. Wojack Poster Presentations 18 November 2012 Pages: 174 - 175
High Level Quinolone Resistance among Escherichia coli Clinical Isolates T. AlarcónJ. PitaM. López-Brea Poster Presentations 18 November 2012 Pages: 176 - 176
Emergence of Resistance of Uropathogens to Quinolones Kurt G. NaberWolfgang WitteBernd Wiedemann Poster Presentations 18 November 2012 Pages: 177 - 178
Resistance to Quinolones and Other Antibiotics Assessed by Factor Analysis L. LeiboviciA. J. WysenbeekM. Drucker Poster Presentations 18 November 2012 Pages: 179 - 179
In Vitro and In Vivo Antibacterial Activity of E-4868 M. A. XicotaR. CollJ. Guinea Poster Presentations 18 November 2012 Pages: 180 - 180
In Vitro Activities of AM-1155 against Chlamydia spp. and M. avium Complex R. SoejimaN. MiyashitaY. Niki Poster Presentations 18 November 2012 Pages: 181 - 181
In Vitro Antibacterial Activity of AM-1155 K. HiraiT. YasueK. Nishino Poster Presentations 18 November 2012 Pages: 182 - 183
Comparative In Vitro Activity of AM-1155, a New Quinolone, against Anaerobic Bacteria K. UenoK. WatanabeY. Tanaka Poster Presentations 18 November 2012 Pages: 184 - 186
In Vitro Activity of PD 131628 against Anaerobic Bacteria C. E. NordA. Hagelbäck Poster Presentations 18 November 2012 Pages: 187 - 187
Comparative In Vitro Activity of PD 131628, the Microbiologically Active Constituent of the Prodrug CI-990 (PD 131112) David FelminghamM. J. RobbinsR. N. Gruneberg Poster Presentations 18 November 2012 Pages: 188 - 189
In Vitro Activity of PD 131628 and Effects on Virulence and OMPs P. CiprianiA. GiordanoF. Filadoro Poster Presentations 18 November 2012 Pages: 190 - 191
Comparative In Vitro Antibacterial Activity of PD 131628, the Active Metabolite of CI-990 J. J. CallananD. O. J. RoditiA. A. Forder Poster Presentations 18 November 2012 Pages: 192 - 193
Susceptibility of 170 Penicillin-Susceptible and -Resistant Pneumococci to Various Antimicrobials S. K. SpanglerM. R. JacobsPeter C. Appelbaum Poster Presentations 18 November 2012 Pages: 194 - 195
Activity of Quinolone Antibacterials against Streptococcus pneumoniae I. MorrisseyJ. T. Smith Poster Presentations 18 November 2012 Pages: 196 - 197
Induction of Resistance of Streptococcus pneumoniae to Levofloxacin, Ciprofloxacin and Norfloxacin In Vitro K. P. FuS. C. LafredoB. D. Foleno Poster Presentations 18 November 2012 Pages: 198 - 198
Comparative In Vitro Activity of Sparfloxacin against Gram-Positive Cocci Sesin KocagözDeniz GürH. Erdal Akalin Poster Presentations 18 November 2012 Pages: 199 - 200
Increased Incidence of Gram-Positive Pathogens Subsequent to Quinolone Therapy in UTI Margareta TauferH. MailerG. Wandschneider Poster Presentations 18 November 2012 Pages: 201 - 201
